RxDoctor Payments Data

Reza Khoshini, MD

Internal Medicine · San Diego, CANPI 1184772014

Payments from drug & device makers

$5,051in general payments, 2019–2025

Across 178 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Medical Systems Corporation$1K
  • AbbVie$1K
  • Johnson & Johnson$483
  • Takeda Pharmaceuticals U.S.A., Inc.$291
  • Pfizer$249
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$143
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$1,45029%
  • Food & beverage$3,57971%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,051 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$156,315
Medicare patients
521
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide28$31,057
TrulancePlecanatide20$19,701
Dexlansoprazole DrDexlansoprazole25$8,655
MotegrityPrucalopride Succinate13$8,555
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates78$4,335
Pantoprazole Sodium203$3,447
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,608
Celecoxib11$1,571
Omeprazole69$993
Esomeprazole Magnesium13$642
Lansoprazole11$504
Famotidine19$213
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$104
Ondansetron OdtOndansetron13$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,308$31,05728 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$143$19,70120 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$291$8,55513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →